1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung Biologics to Buy Biogen's Stake in JV

01/27/2022 | 07:22pm EDT

By Stephen Nakrosis


Biogen Inc. on Thursday said it agreed to sell its equity stake in the Samsung Bioepis joint venture to Samsung Biologics in a deal that could be worth $2.3 billion.

Samsung Bioepis is a biopharmaceutical company.

The deal will see Biogen receive $1 billion in cash at closing, the company said. It will also receive $1.25 billion in deferred payments, with $812.5 million due at the first anniversary and $437.5 million due at the second anniversary of the transaction closing.

Biogen is eligible to receive up to $50 million in contingency payments, it said.

Following the close of the deal, the companies will continue with their exclusive agreements, including commercialization of their current portfolio, according to Biogen.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

01-27-22 1922ET

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 3.40% 199.65 Delayed Quote.-16.78%
SAMSUNG BIOLOGICS CO.,LTD. 1.51% 808000 End-of-day quote.-10.52%
SAMSUNG ELECTRONICS CO., LTD. 0.74% 68000 End-of-day quote.-13.15%
All news about SAMSUNG BIOLOGICS CO.,LTD.
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/27SAMSUNG BIOLOGICS : Material Business Matters Related to Investment Decisions
PU
04/21SAMSUNG BIOLOGICS : Results of issuance (Voluntary Disclosure)
PU
04/05Allakos Inc. Enters into A Master Development Services Agreement with Samsung Biologics..
CI
04/01Samsung C&T - Samsung Life Science Fund makes first investment in US biotech firm Jagua..
AQ
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,56 B 1,56 B
Net income 2022 542 B 0,43 B 0,43 B
Net Debt 2022 566 B 0,44 B 0,44 B
P/E ratio 2022 102x
Yield 2022 -
Capitalization 57 509 B 45 166 M 45 166 M
EV / Sales 2022 29,2x
EV / Sales 2023 25,6x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 808 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Doyoung Heo Head-Finance & Vice President
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 166
CSL LIMITED-5.35%93 148
WUXI BIOLOGICS (CAYMAN) INC.-39.17%30 261
BIOGEN INC.-16.78%29 239
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%22 130
UCB-13.28%17 367